- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical- stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Andrew Saik to the role of Chief Financial Officer and Treasurer reporting to Chairperson, Chief Executive Officer, and President, John Houston, Ph.D. "It is a pleasure to welcome Andrew as our ne ...

- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Andrew Saik to the role of Chief Financial Officer and Treasurer reporting to Chairperson, Chief Executive Officer, and President, John Houston, Ph.D. "It is a pleasure to welcome Andrew as our new ...

Core Insights - Arvinas, Inc. presented promising preclinical data for its investigational PROTAC BCL6 degrader ARV-393, demonstrating anti-tumor activity in B-cell lymphoma models [1][2][3] - The company also highlighted the potential of its PROTAC LRRK2 degraders for treating neurodegenerative diseases at the Biennial International LRRK2 Meeting [1][4] Group 1: ARV-393 and B-cell Lymphoma - ARV-393 effectively degraded the BCL6 protein and inhibited cell growth in various B-cell lymphoma models, including diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma [2][3] - The investigational drug showed tumor growth inhibition and regression in multiple patient-derived xenograft (PDX) models of non-Hodgkin lymphoma (NHL) [2][3] - The results suggest that ARV-393 could be a potential new treatment for patients with certain types of NHL, particularly those unresponsive to existing therapies [3] Group 2: PROTAC LRRK2 Degraders - Preclinical studies indicated that the oral PROTAC LRRK2 degraders demonstrated full target engagement and near-complete LRRK2 degradation in mouse models [4] - Compared to experimental LRRK2 kinase inhibitors, PROTAC LRRK2 degraders showed a more favorable safety profile with less Type II pneumocyte enlargement [4] - These findings suggest a wide therapeutic index and manageable safety profile for PROTAC degraders in treating neurodegenerative diseases [4] Group 3: Clinical Development - ARV-393 is currently in a phase 1 clinical trial for patients with non-Hodgkin lymphoma [4][5] - Arvinas is also investigating ARV-102, an oral PROTAC LRRK2 degrader, in a phase 1 clinical trial involving healthy volunteers [4][6]

– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma –  – Preclinical data presented at the Biennial International LRRK2 Meeting highlighted the promise of PROTAC®-induced leucine-rich repeat kinase 2 (LRRK2) degradation as a potential treatment for neurodegenerative diseases –  NEW HAVEN, Conn., June 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creatin ...

NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced Ian Taylor, Ph.D. has been promoted to President of Research and Development and Angela Cacace, Ph.D. has also been promoted and will succeed Dr. Taylor as Chief Scientific Officer of the company. Dr. Taylor and Dr. Cacace will assume these new roles effective immediately and report to John Houston, Ph.D., Chair ...

NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced Ian Taylor, Ph.D. has been promoted to President of Research and Development and Angela Cacace, Ph.D. has also been promoted and will succeed Dr. Taylor as Chief Scientific Officer of the company. Dr. Taylor and Dr. Cacace will assume these new roles effective immediately and report to John Houston, Ph.D., Chai ...

NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on Thursday, June 6 in New York City. John Houston, Ph.D., Chairperson, Chief Executive Officer and President, and Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, will participate in a firesid ...

Core Insights - Arvinas, Inc. announced the acceptance of two abstracts for presentation at the 2024 American Society of Clinical Oncology Annual Congress, focusing on ARV-766 for prostate cancer and TACTIVE-K for breast cancer treatment [1][2] Group 1: Presentation Details - The first presentation is titled "ARV-766, a PROteolysis TArgeting Chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): initial results of a phase 1/2 study," scheduled for June 3, 2024 [2] - The second presentation is titled "TACTIVE-K: phase 1b/2 study of vepdegestrant, a PROTAC estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/HER2- advanced breast cancer," scheduled for June 2, 2024 [2] Group 2: Product Information - ARV-766 is an investigational PROTAC protein degrader targeting the androgen receptor, showing preclinical activity against both wild type and mutated AR tumors, which are common in resistance to current therapies [3] - Vepdegestrant is an investigational PROTAC protein degrader targeting the estrogen receptor for ER+/HER2- breast cancer, developed in collaboration with Pfizer, and has received Fast Track designation from the FDA [4] Group 3: Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies that degrade disease-causing proteins using its proprietary PROTAC® Discovery Engine platform [5] - The company has four clinical-stage programs, including vepdegestrant and ARV-766, targeting various cancers and neurodegenerative disorders [6]

NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational oral PROteolysis Targeting Chimera (PROTAC®) ER degrader, in combination with Pfizer’s atirmociclib (PF-07220060), an investigational CDK4 inhibitor, were accepted for presentation at the 2024 American Society of Clinical Oncology Annual Congress held May ...

– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023 – – At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months (95% CI: 8.1-NR) – – Across all vepdegestrant dose groups, ...